About: Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma
Creator	Zhou, · Keller, Lorraine Kurupati, Raj Xiang, Zhiquan Ertl, C Hildegund, ·
topic	covid:6469f23b0ff4f266e861252af11ab413d9682029#this
Source	Medline; PMC
abstract	Human immunotherapy with checkpoint blockades has achieved significant breakthroughs in recent years. In this study, a checkpoint blockade vaccine for canine melanoma was tested for safety and immunogenicity. Five healthy adult dogs received a mixture of three replication-defective chimpanzee-derived adenoviral vectors, one expressing mouse fibroblast-associated protein (mFAP) and the others expressing canine melanoma-associated antigens Trp-1 or Trp-2 fused into Herpes Simplex-1 glycoprotein D, a checkpoint inhibitor of herpes virus entry mediator (HVEM) pathways. The vaccine mixture was shown to be well tolerated and increased frequencies of canineTrp-1-specific activated CD8(+) and CD4(+) T cells secreting interferon-(IFN)-γ, tumor necrosis factor (TNF)-α, or interleukin (IL)-2 alone or in combinations in four and five out of five dogs, respectively. To avoid excessive bleeds, responses to cTrp-2 were not analyzed. All dogs responded with increased frequencies of mFAP-specific activated CD8(+) and CD4(+) T cells. The results of this safety/immunogenicity trial invite further testing of this checkpoint blockade vaccine combination in dogs with melanoma. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00262-018-2201-5) contains supplementary material, which is available to authorized users.
has issue date	2018-07-26(xsd:dateTime)
bibo:doi	10.1007/s00262-018-2201-5
bibo:pmid	30051333
has license	no-cc
sha1sum (hex)	6469f23b0ff4f266e861252af11ab413d9682029
schema:url	https://doi.org/10.1007/s00262-018-2201-5
resource representing a document's title	Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma
has PubMed Central identifier	PMC7080056
has PubMed identifier	30051333
schema:publication	Cancer Immunol Immunother
resource representing a document's body	covid:6469f23b0ff4f266e861252af11ab413d9682029#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/6469f23b0ff4f266e861252af11ab413d9682029
is schema:about of	named entity 'fused' named entity 'combinations' named entity 'checkpoint' named entity 'canine' named entity 'responses' named entity 'Safety' covid:arg/6469f23b0ff4f266e861252af11ab413d9682029 named entity 'blockade' named entity 'specific' named entity 'CD8' named entity 'T cells' named entity 'mouse' named entity 'vaccine' named entity 'tolerated' named entity 'vaccine' named entity 'melanoma' named entity 'checkpoint blockade' named entity 'fibroblast' named entity 'CD4 +' named entity 'melanoma' named entity 'checkpoint blockade' named entity 'canine' named entity 'HVEM' named entity 'mediator' named entity 'protein' named entity 'invite' named entity 'CD95' named entity 'LAL' named entity 'CD4 +' named entity 'IFN-γ' named entity 'incubation' named entity 'hematological' named entity 'glucose' named entity 'Clinical Research' named entity 'Recombinant' named entity 'CD8 +' named entity 'BTLA' named entity 'mice' named entity 'vaccination' named entity 'vector' named entity 'median survival time' named entity 'melanoma' named entity 'CTLA-4' named entity 'Bordetella' named entity 'relative humidity' named entity 'restriction enzyme' named entity 'systemic side effects' named entity 'vaccine' named entity 'CD28' named entity 'CD95' named entity 'CD8 +' named entity 'CD4 +' named entity 'antibody' named entity 'CD8 +' named entity 'HVEM' named entity 'Antibodies' named entity 'banding patterns' named entity 'vaccination' named entity 'antibodies' named entity 'IFNγ' named entity 'DNA vaccine' named entity 'veterinarian' named entity 'T-cell' named entity 'antibodies' named entity 'cancer vaccine' named entity 'tumor' named entity 'Neutralizing antibodies' named entity 'peptide' named entity 'HVEM' named entity 'restriction enzyme' named entity 'CD4 +' named entity 'PBMCs' named entity 'hexon' named entity 'vaccination'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software